Updating results

85 results for Depression in Children and Adolescents

Sort: Date | Relevance

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

Technology appraisal guidance Published November 2013

Smoking: acute, maternity and mental health services (PH48)

This guideline covers helping people to stop smoking in acute, maternity and mental health services. It promotes smokefree policies and services and recommends effective ways to help people stop smoking or to abstain from smoking while using or working in secondary care settings.

Public health guideline Published November 2013

Weight management: lifestyle services for overweight or obese children and young people (PH47)

This guideline covers lifestyle weight management services for children and young people aged under 18 who are overweight or obese. It advises how to deliver effective weight management programmes that support children and young people to change their lifestyle and manage their weight.

Public health guideline Published October 2013

Depression in children and young people (QS48)

This quality standard covers diagnosing and managing depression in children and young people (aged 5 to 18). It describes high-quality care in priority areas for improvement.

Quality standard Published September 2013

Autism spectrum disorder in under 19s: support and management (CG170)

This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.

Clinical guideline Published August 2013

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

New treatment approved for adolescents with bipolar disorder

NICE has recommended the use of aripiprazole (Abilify) as an option for treating moderate to severe manic episodes in adolescents with bipolar disorder.

News Published July 2013 Last updated July 2013

Self‑harm (QS34)

This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.

Quality standard Published June 2013

Physical activity: brief advice for adults in primary care (PH44)

This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.

Public health guideline Published May 2013

Social anxiety disorder: recognition, assessment and treatment (CG159)

This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.

Clinical guideline Published May 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

Summary of the evidence on lisdexamfetamine dimesylate for attention defecit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published May 2013

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Antisocial personality disorder: prevention and management (CG77)

This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.

Clinical guideline Published January 2009 Last updated March 2013

Epilepsy in children and young people (QS27)

This quality standard covers diagnosing, treating and managing epilepsy and seizures in children and young people (under 18). It describes high-quality care in priority areas for improvement.

Quality standard Published February 2013

Epilepsy in adults (QS26)

This quality standard covers diagnosing, treating and managing epilepsy and seizures in adults (aged 18 and older). It describes high-quality care in priority areas for improvement.

Quality standard Published February 2013

Social and emotional wellbeing: early years (PH40)

This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.

Public health guideline Published October 2012

Self-harm in over 8s: long-term management (CG133)

This guideline covers the longer-term psychological treatment and management of self-harm in people aged 8 and over. It aims to improve the quality of care and support for people who self harm and covers both single and recurrent episodes of self-harm.

Clinical guideline Published November 2011

Alcohol-use disorders: diagnosis and management (QS11)

This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol problem, and caring for people with alcohol-related health problems, such as alcohol dependence or Wernicke's encephalopathy. It also covers support for their families and carers. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2011

Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10–17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

Clinical guideline Published February 2011

Cardiovascular disease prevention (PH25)

This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.

Public health guideline Published June 2010

Alcohol-use disorders: prevention (PH24)

This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.

Public health guideline Published June 2010

Social and emotional wellbeing in secondary education (PH20)

This guideline covers interventions to support social and emotional wellbeing among young people aged 11–19 years who are in full-time education. It aims to promote good social, emotional and psychological health to protect young people against behavioural and health problems.

Public health guideline Published September 2009

Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)

Technology appraisal guidance Published February 2009

Physical activity for children and young people (PH17)

This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.

Public health guideline Published January 2009

Borderline personality disorder: recognition and management (CG78)

This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.

Clinical guideline Published January 2009

Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

Technology appraisal guidance Published September 2008

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Social and emotional wellbeing in primary education (PH12)

This guideline covers approaches to promoting social and emotional wellbeing in children aged 4 to 11 years in primary education. It includes planning and delivering programmes and activities to help children develop social and emotional skills and wellbeing. It also covers identifying signs of anxiety or social and emotional problems in children and how to address them.

Public health guideline Published March 2008

Sexually transmitted infections and under-18 conceptions: prevention (PH3)

This guideline covers one-to-one interventions to prevent sexually transmitted infections (STIs) and under-18 conceptions. The aim is to reduce the transmission of chlamydia and other STIs, including HIV, and reduce the rate of pregnancies among women aged under 18.

Public health guideline Published February 2007

Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

Clinical guideline Published November 2005

Self-harm in over 8s: short-term management and prevention of recurrence (CG16)

This guideline covers the short-term management and prevention of self-harm in people aged 8 and over, regardless of whether accompanied by mental illness. It covers the first 48 hours following an act of self-harm, but does not address the longer-term psychiatric care of people who self-harm.

Clinical guideline Published July 2004

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Migalastat for treating Fabry disease (HST4)

marketing authorisation in the UK for 'long‑term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis...

Technology appraisal guidance